Versacross Steerable Access Solution
Payments companies reported to CMS as associated with Versacross Steerable Access Solution. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Versacross Steerable Access Solution, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Versacross Steerable Access Solution
These are the largest totals companies reported as associated with Versacross Steerable Access Solution. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Augustin Delago | Albany, NY | Cardiovascular Disease | $17,510.67 |
| Areen Al-Taie | Florence, AL | Interventional Cardiology | $1,149.70 |
| Samual Bass | Boise, ID | Cardiovascular Disease | $528.26 |
| Murali Bathina | Caldwell, ID | Cardiovascular Disease | $528.24 |
| Shannon Mcconnaughey | Meridian, ID | Cardiovascular Disease | $528.24 |
| Stefanie Fry | Boise, ID | Cardiovascular Disease | $528.22 |
| Marcos Daccarett | Boise, ID | Clinical Cardiac Electrophysiology | $528.21 |
| Robert Duerr | Boise, ID | Interventional Cardiology | $528.21 |
| Jeffrey Heslop | Boise, ID | Interventional Cardiology | $512.81 |
| Adam Grimaldi | Boise, ID | Clinical Cardiac Electrophysiology | $512.80 |
Prescribed Versacross Steerable Access Solution?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.